Related Experiment Video

Updated: Feb 26, 2026

Techniques of Sleeve Gastrectomy and Modified Roux-en-Y Gastric Bypass in Mice
10:05

Techniques of Sleeve Gastrectomy and Modified Roux-en-Y Gastric Bypass in Mice

Published on: March 20, 2017

12.7K

Age increases MCP-1 level in association with bariatric surgery operating time and metabolic risk severity

S K Malin1,2,3, J L Kaplan3,4, L Meng3

  • 1Department of Kinesiology University of Virginia Charlottesville USA.

Obesity Science & Practice
|July 15, 2017
PubMed

Insights

Inflammation marker monocyte chemoattractant protein-1 (MCP-1) is linked to longer operating times and higher metabolic risk in older bariatric surgery patients. Addressing inflammation before surgery may improve outcomes.

Area of Science:

  • Bariatric Surgery
  • Inflammation and Metabolism
  • Surgical Outcomes

Background:

  • Older bariatric surgery patients often present with increased inflammation and metabolic risk.
  • Understanding the role of inflammation in surgical outcomes is crucial for optimizing patient care.
  • Monocyte chemoattractant protein-1 (MCP-1) is a key inflammatory marker implicated in metabolic diseases.

Purpose of the Study:

  • To assess the association between inflammation, specifically MCP-1 levels, and operating time in younger versus older bariatric surgery patients.
  • To investigate the relationship between MCP-1, metabolic risk severity, and glycaemic control in different age groups undergoing bariatric surgery.

Main Methods:

  • A cohort of younger (n=55) and older (n=48) bariatric surgery patients were studied pre-operatively.
  • Assessed parameters included blood pressure, glycaemic control (HbA1c), lipids, and serum MCP-1.
  • Omental adipose tissue biopsies were collected for MCP-1 protein analysis; operating time served as a proxy for surgical difficulty.

Main Results:

  • Older patients exhibited higher HbA1c and elevated circulating MCP-1 levels compared to younger patients.
  • Operating time was significantly longer in older individuals.
  • Serum MCP-1 correlated with increased metabolic risk severity, and operating time was linked to HbA1c and omental MCP-1.

Conclusions:

  • MCP-1 is associated with longer operating times and greater metabolic risk in older bariatric patients, independent of glycaemic control.
  • These findings suggest that pre-operative inflammation may impact surgical complexity and outcomes.
  • Targeting inflammation prior to bariatric surgery could potentially enhance its effectiveness and improve patient recovery.
Abstract

Keywords:
Glycaemic controlinflammationinsulin resistancemetabolic syndrome

More Related Videos

Sleeve Gastrectomy in Mice using Surgical Clips05:16

Sleeve Gastrectomy in Mice using Surgical Clips

Published on: November 14, 2020

7.5K
Roux-en-Y Gastric Bypass Operation in Rats07:37

Roux-en-Y Gastric Bypass Operation in Rats

Published on: June 11, 2012

24.4K

Related Concept Videos

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
322
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.4K
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
249